| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03639766 Details | 2021-06-30 Interventional | 4 | 3 | Botulinum Toxin… abobotulinumtox… Raynaud Disease Raynaud Phenome… | Time and resource constraints - | |||
| NCT03567616 2017-004232-11 Details | 2021-06-30 Interventional | 2 | 8 | Dexamethasone Pomalidomide Venetoclax Multiple Myelom… Neoplasms, Plas… | Following results of the primary progression-free survival analysis from Study NCT02755597,
company-sponsored MM studies were placed on partial clinical hold (PCH). Sponsor did not pursue
release of the PCH for this study. - | |||
| NCT03285646 2017-001943-12 Details | 2021-06-30 Interventional | 3 | 63 | Fasinumab Back Pain Low Back Pain Osteoarthritis Osteoarthritis,… Chronic Low Bac… | Due to implementation of an urgent safety measure, enrollment and dosing in R475-PN-1612 was
stopped; enrolled participants entered the 20-week safety follow-up Enrollment and study drug administration was stopped due to an urgent safety measure. As a result the small number of participants enrolled in this study limited the interpretability of the efficacy results. | |||
| NCT02631148 Details | 2021-06-30 Interventional | 2 | 12 | Melatonin Prediabetic Sta… Obesity | International shortage of the chemical para-aminohippuric acid (PAH) due to manufacturing
changes, led to inability to perform key measurements to meet trial objectives - | |||
| NCT04943692 Details | 2021-06-29 Interventional | 3 | - | Metformin Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes | Administrative decision of the investigation direction - | |||
| NCT04322396 Details | 2021-06-29 Interventional | 2 | 117 | Azithromycin Hydroxychloroqu… Communicable Di… Coronavirus Inf… Infections Virus Diseases Corona Virus In… Infection Viral | Recommended by the DSMB Early termination based on recommendations from the DSMB leading to small numbers of subjects analyzed. | |||
| NCT01812759 Details | 2021-06-29 Interventional | 4 | 3 | Fentanyl Hydromorphone Emergencies Pain | - - | |||
| NCT00046163 Details | 2021-06-29 Interventional | 4 | - | Midodrine Hypotension Hypotension, Or… | Study was terminated due to poor enrollment - | |||
| NCT04762511 Details | 2021-06-28 Interventional | 1 | 17 | Vaccines Herpes Simplex | To enable development of an enhanced version of the vaccine - | |||
| NCT04534803 Details | 2021-06-28 Interventional | 3 | 0 | BCG Vaccine COVID-19 Covid19 | At this time it has been decided by the study team the the study will no longer take place in
the United States. - | |||
| NCT03032042 Details | 2021-06-28 Interventional | 4 | 0 | Albendazole Azithromycin Helminthiasis Helminth Infect… | We were not able to secure IRB approval in the timeline necessary to do this study. - | |||
| NCT04131517 2019-002194-54 Details | 2021-06-24 Interventional | 1 | 14 | Ethinyl Estradi… Ethinyl estradi… Padsevonil Healthy Female … | Based on available data, UCB has decided to stop development of padsevonil as adjunctive
treatment of focal-onset seizures The study was terminated on 22 May 2020 because the program developing padsevonil in focal-onset seizures was stopped. | |||
| NCT03577899 Details | 2021-06-24 Interventional | 3 | 1157 | Aflibercept Macular Degener… Wet Macular Deg… Neovascular Age… | desired primary endpoint was not met - | |||
| NCT01928446 Details | 2021-06-24 Interventional | 2/3 | 519 | Lithium Carbona… Bipolar Disorde… Depressive Diso… Mood Disorders Suicide Suicide, Attemp… | terminated early due to non-safety related DMC recommendations - | |||
| NCT00809354 2008-004815-37 Details | 2021-06-24 Interventional | 3 | 2720 | Anti-Inflammato… Tanezumab Osteoarthritis Osteoarthritis,… Arthritis | See termination reason in detailed description. - | |||
| NCT00223938 Details | 2021-06-24 Interventional | 4 | 112 | Ferric Compound… Ferric gluconat… Anemia | The study was terminated because of significant enrollment challenges - | |||
| NCT03630952 Details | 2021-06-23 Interventional | 3 | 1157 | Aflibercept Macular Degener… Wet Macular Deg… Neovascular Age… | desired primary endpoint was not met - | |||
| NCT04356677 Details | 2021-06-22 Interventional | 1 | 0 | Ribavirin COVID-19 COVID19 | Due to pandemic status changing in Canada prior to investigative sites being initiated for
participation, and that concurrent participant recruitment in the global study BHC-RIB-5401-GL
will achieve target enrollment across all countries. - | |||
| NCT03219866 Details | 2021-06-22 Interventional | 4 | 40 | Budesonide Fluticasone-Sal… Ipratropium Tiotropium Brom… Pulmonary Disea… COPD COPD Exacerbati… | Lower enrollment than Sponsor expected - Sponsor stopped study - | |||
| NCT03190213 Details | 2021-06-22 Interventional | 2 | 6 | Pembrolizumab Carcinoma, Neur… Neuroendocrine … | Update on clinical development: after discussions with the drug manufacturer, the PI has
decided to discontinue the trial. - |